HP802-247: Difference between revisions
mNo edit summary |
WikiModEn2 (talk | contribs) Wikify. |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
'''{{FULLPAGENAME}}''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose [[skin]] will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be [[skin]] graft.<ref>{{REFweb | |||
| last= | |last= | ||
| first= | |first= | ||
| date=2012-08-03 | |date=2012-08-03 | ||
| title=Spray-on-skin' treatment for leg ulcers | |title=Spray-on-skin' treatment for leg ulcers | ||
| url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | |url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | ||
| publisher=NHS | |publisher=NHS | ||
| accessdate=2012-11-24 | |accessdate=2012-11-24 | ||
}}</ref> | }}</ref> | ||
== HP802-247 == | == HP802-247 == | ||
The new spray (HP802-247) consisted of a combination of donated skin cells and proteins. | The new spray (HP802-247) consisted of a combination of donated [[skin]] cells and proteins. | ||
The study was conducted by researchers from the University of Miami and other institutions in the | The study was conducted by researchers from the {{UNI|University of Miami|UMiami}} and other institutions in the [[United States]] and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal ''The Lancet''.<ref>{{REFweb | ||
| last= | |last= | ||
| first= | |first= | ||
| date=201209 | |date=201209 | ||
| title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial | |title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial | ||
| url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract | |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract | ||
| publisher=The Lancet | |publisher=The Lancet | ||
| accessdate=2012-11-24 | |accessdate=2012-11-24 | ||
}}</ref> | }}</ref> | ||
The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials. | The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the [[skin]], and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn [[foreskin]] samples (removed during [[circumcision]]). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials. | ||
{{REF}} | {{REF}} | ||
[[Category:Foreskin | [[Category:Foreskin product]] | ||
[[Category:Financial | [[Category:Financial gain]] | ||
[[Category:From CircLeaks]] | [[Category:From CircLeaks]] | ||
[[Category:From IntactWiki]] | [[Category:From IntactWiki]] | ||
[[de:{{FULLPAGENAME}}]] | |||